Amyris Raises $84.8M in IPO, Prices at $16, Well Below Expected Range

NEW YORK, Sept 27 (Reuters) - Amyris Inc (AMRS.O), which uses yeast to convert plant sugars into the building blocks of anti-malarial drugs, priced shares in its initial public offering below the range on Monday, according to an underwriter.